An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease
Latest Information Update: 19 Sep 2024
Price :
$35 *
At a glance
- Drugs KL 1333 (Primary)
- Indications Mitochondrial disorders
- Focus Registrational; Therapeutic Use
- Acronyms FALCON
- Sponsors Abliva
- 18 Jul 2024 According to an Abliva media release, the independent Data Monitoring Committee (DMC) recommended continuing the study without modification.
- 18 Jul 2024 According to an Abliva media release, the company plans to start the final wave of FALCON study recruitment in the second half of 2024.
- 18 Jul 2024 Interim results presented in an Abliva Media Release.